MannKind | MNKD - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Adma Biologics USD 76.41M 6.8M 2025-12
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Insmed USD 506.24M 7.31M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 21.2M 32.13M 2026-03
MannKind USD 110.9M 8.74M 2026-03
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Novavax USD 126.2M 23.62M 2025-12
Novo Nordisk DKK 6.5B 32.8B 2025-06
Pfizer USD 90.1B 77.19B 2026-03
Sanofi EUR 9.31B 1.2B 2026-03
Xencor USD 82.38M 513K 2026-03